HC Wainwright & Co. Reiterates Buy on Sernova Biotherapeutics, Maintains C$1 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.4%

Neg 0% Neu 87.4% Pos 0%

HC Wainwright & Co. analyst Joseph Pantginis reiterates Sernova Biotherapeutics (TSX:SVA) with a Buy and maintains C$1 price target.